Arcellx to Attend Two Investor Conferences in May 2024

Arcellx, Inc., a clinical-stage biotechnology firm based in Redwood City, California, is pioneering advancements in cell therapy with a focus on innovative immunotherapies for cancer and other chronic diseases. The company recently announced its participation in two significant investor conferences: the BofA Securities Health Care Conference 2024 and the TD Cowen 5th Annual Oncology Innovation Summit.

The BofA Securities Health Care Conference will be held in person on May 14, with Arcellx's presentation scheduled for 3:40 p.m. PT. Meanwhile, the TD Cowen Oncology Innovation Summit will take place virtually on May 28, featuring a fireside chat at 1:00 p.m. PT. Both events will be webcast live, accessible through Arcellx’s website, and replays will be available for 30 days following the events.

Arcellx's mission is to revolutionize cell therapy, aiming to make treatments safer, more effective, and more accessible. The company’s flagship product, anito-cel (formerly CART-ddBCMA), is under Phase 2 pivotal trial for treating relapsed or refractory multiple myeloma (rrMM). This product has received multiple designations from the U.S. Food and Drug Administration, including Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy.

Beyond anito-cel, Arcellx is also advancing its ARC-SparX program, a dosable and controllable CAR T therapy. This program includes two Phase 1 trials: ACLX-001 for rrMM and ACLX-002 for relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!